<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04489433</url>
  </required_header>
  <id_info>
    <org_study_id>CDRB436B2005CM</org_study_id>
    <nct_id>NCT04489433</nct_id>
  </id_info>
  <brief_title>Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma</brief_title>
  <official_title>Managed Access Program (MAP) Cohort Treatment Plan CDRB436B2005CM to Provide Access to Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in&#xD;
      combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed&#xD;
      with metastatic melanoma BRAF mutation-positive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient's Treating Physician should follow the suggested treatment guidelines and comply&#xD;
      with all local health authority regulations.&#xD;
&#xD;
      The requesting Treating Physician submitted a request for access to drug (often referred to&#xD;
      as Compassionate Use) to Novartis which was reviewed and approved by the medical team&#xD;
      experienced with the drug and indication.&#xD;
&#xD;
      This program will provide access to patients until:&#xD;
&#xD;
        -  All participating countries have received marketing authorization and product is&#xD;
           commercially available and accessible to all participating patient(s) or&#xD;
&#xD;
        -  Alternative treatment options are available and/or&#xD;
&#xD;
        -  In case of changes in the safety profile or a lack of overall efficacy of the product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib and Trametinib</intervention_name>
    <description>The starting dose of the combination treatment will be administered as follows:&#xD;
Dabrafenib, 150 mg, twice daily (BID);&#xD;
Trametinib, 2.0 mg, once daily (QD)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients eligible for inclusion in this Treatment Plan have to meet all of the following&#xD;
        criteria:&#xD;
&#xD;
          1. Has or is willing to give consent to the Treating Physician in accordance with the&#xD;
             local regulatory requirements, with age at the time of consent ≥18 years.&#xD;
&#xD;
          2. Has confirmed BRAF V600 or other BRAF activating mutation-positive metastatic&#xD;
             melanoma. Histologically Stage IIIC (unresectable) or Stage IV (metastatic) cutaneous&#xD;
             melanoma with confirmed BRAF V600E/K positive mutation.&#xD;
&#xD;
          3. All clinical trials that the patient might qualify for have been ruled out.&#xD;
&#xD;
          4. Is receiving care at a clinical site with a Treating Physician who has experience with&#xD;
             administering investigational agents for the end-stage melanoma population, or the&#xD;
             patient is willing and/or able to travel to a site and receive treatment under the&#xD;
             guidance of physician with this experience. NOTE: The latter option would require the&#xD;
             patient being evaluated in advance by the Treating Physician at the experienced site&#xD;
             and his/her agreement to assume responsibility for the care of the patient.&#xD;
&#xD;
          5. Is able to retain oral medication and swallow tablets/capsules (appropriate exceptions&#xD;
             allowed for patients who are unable to swallow tablets/capsules - this is subject to&#xD;
             availability of alternative (liquid) oral formulations).&#xD;
&#xD;
          6. Does not require treatment with any (other) anti-cancer medication (exceptions might&#xD;
             be allowed and are subject to individual evaluation).&#xD;
&#xD;
          7. For patients with active brain metastases: the patient does not require or is&#xD;
             ineligible for immediate local treatment.&#xD;
&#xD;
          8. Is not eligible for participation in any of the IMP's ongoing clinical trials or has&#xD;
             recently completed a clinical trial that has been terminated and, after considering&#xD;
             other options (e.g., trial extensions, amendments, etc.), the clinical team has&#xD;
             determined that treatment is necessary and there are no other feasible alternatives&#xD;
             for the patient.&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (or equivalent)&#xD;
             and is in stable clinical condition. NOTE: patient in rapidly deteriorating clinical&#xD;
             condition prior to start of therapy should not be considered for this program.&#xD;
&#xD;
         10. Does not require treatment with prohibited concomitant medications&#xD;
&#xD;
         11. Women of childbearing potential must have a negative serum beta-human chorionic&#xD;
             gonadotropin (HCG) pregnancy test performed within 14 days prior to starting&#xD;
             dabrafenib and trametinib treatment. Subjects with a positive pregnancy test result&#xD;
             must be excluded from the program. Subjects with a negative pregnancy test result must&#xD;
             agree to use an effective contraception method as described below throughout the&#xD;
             treatment period and for a total of 4 months following the last dose of treatment.&#xD;
&#xD;
        Contraceptive Methods for Females of Childbearing Potential:&#xD;
&#xD;
          -  An intrauterine device with a documented failure rate of less than 1% per year&#xD;
&#xD;
          -  Vasectomized partner who is sterile prior to the female patient's entry into the&#xD;
             Compassionate Use program, and this male is the sole sexual partner for that female.&#xD;
&#xD;
          -  Complete abstinence from sexual intercourse for 14 days prior to first dose of&#xD;
             treatment, through the dosing period, and for at least 4 months after the last dose of&#xD;
             treatment. Abstinence is only acceptable when in line with the preferred and usual&#xD;
             lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation,&#xD;
             symptothermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods&#xD;
             of contraception.&#xD;
&#xD;
          -  Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault&#xD;
             caps) with vaginal spermicidal agent (foam/gel/cream/suppository).&#xD;
&#xD;
        Note: Hormonal-based methods (e.g., oral contraceptives) are not permitted as contraception&#xD;
        due to potential drug-drug interactions with dabrafenib.&#xD;
&#xD;
        Females Not of Childbearing Potential Non-childbearing potential (i.e., physiologically&#xD;
        incapable of becoming pregnant) is defined as any female who has had a documented&#xD;
        hysterectomy, bilateral oophorectomy (ovariectomy), bilateral tubal ligation or tubal&#xD;
        occlusion, or is post-menopausal.&#xD;
&#xD;
        A practical definition accepts menopause after 1 year without menses with an appropriate&#xD;
        clinical profile; e.g., age appropriate, &gt;45 years in the absence of hormone replacement&#xD;
        therapy (HRT). In questionable cases, the patient must have a follicle stimulating hormone&#xD;
        (FSH) value &gt;40 mIU/mL and an estradiol value &lt;40 pg/mL (&lt;140 pmol/L).&#xD;
&#xD;
        Female patients determined not to be post-menopausal must use adequate contraception, as&#xD;
        defined immediately above for females of childbearing potential.&#xD;
&#xD;
        Female subjects who are lactating must discontinue nursing prior to the first dose of&#xD;
        program treatment and must refrain from nursing throughout the treatment period and for 4&#xD;
        months following the last dose of program treatment.&#xD;
&#xD;
        If a subject becomes pregnant during the treatment period of the program, the treatments&#xD;
        should be stopped immediately.&#xD;
&#xD;
        Written patient informed consent must be obtained by the Treating Physician prior to start&#xD;
        of treatment in accordance with the applicable local regulatory requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients eligible for this Treatment Plan must not meet any of the following criteria:&#xD;
&#xD;
          1. Uveal or mucosal melanoma.&#xD;
&#xD;
          2. Female who is pregnant or nursing (patient must discontinue nursing in order to enroll&#xD;
             in the program).&#xD;
&#xD;
             NOTE: Safety and efficacy in pregnant or nursing women has not been investigated.&#xD;
             Inclusion of pregnant or nursing woman may be considered in individually upon review&#xD;
             by the Novartis Country Pharma Organization Medical Advisor/Director.&#xD;
&#xD;
          3. Patients who have any lab abnormalities or AE/SAEs greater than Grade 3 (CTCAE v5.0)&#xD;
&#xD;
          4. Concurrent treatment with other systemic anti-cancer therapies is not allowed, with&#xD;
             the exception of whole brain radiation and brain radiosurgery. Patients who are&#xD;
             currently being treated with another systemic anti-cancer therapy (e.g., chemotherapy,&#xD;
             immune, biologic, or targeted therapy) must discontinue use prior to initiation of&#xD;
             treatment with trametinib and dabrafenib. NOTE: Radiation skin injury has been&#xD;
             reported with concurrent use of dabrafenib and radiation. All AEs/SAEs related to WBRT&#xD;
             (whole brain radiation) or brain radiosurgery are required to resolve to Grade 1 or&#xD;
             less (CTCAE v5.0) prior to start of the Managed Access Program treatment.&#xD;
&#xD;
          5. Patients who have received prior therapy with a BRAF inhibitor other than dabrafenib.&#xD;
&#xD;
             NOTE: Consideration may be given to those patients who have either (1) received prior&#xD;
             BRAF therapy and there is disease progression in the CNS only or (2) discontinued&#xD;
             prior BRAF therapy due to an adverse event that is not likely to recur in response to&#xD;
             treatment with Dabrafenib&#xD;
&#xD;
          6. Presence of any malignancy with confirmed activating RAS mutation. NOTE: Prospective&#xD;
             RAS testing is not required. However, if the results of previous RAS testing are&#xD;
             known, they must be used in assessing eligibility.&#xD;
&#xD;
          7. Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to trametinib or dabrafenib, or excipients or to dimethyl sulfoxide&#xD;
             (DMSO).&#xD;
&#xD;
          8. Any medical conditions or physical examination or clinical laboratory findings which&#xD;
             would put the patient at high risk for an adverse outcome.&#xD;
&#xD;
          9. Current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy.&#xD;
&#xD;
         10. Current evidence of cardiovascular risk including any of the following:&#xD;
&#xD;
               -  LVEF&lt;LLN&#xD;
&#xD;
               -  A QT interval corrected for heart rate using the Bazett's formula greater or&#xD;
                  equal to 480 msec;&#xD;
&#xD;
               -  Clinically significant uncontrolled arrhythmias&#xD;
&#xD;
               -  Acute coronary syndromes (including myocardial infarction and unstable angina).&#xD;
&#xD;
               -  Congestive heart failure ≥ Class II as defined by New York Heart Association&#xD;
&#xD;
         11. Not able to understand and to comply with treatment instructions and requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+81337978748</phone>
  </overall_contact_backup>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>July 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2020</study_first_posted>
  <last_update_submitted>May 2, 2023</last_update_submitted>
  <last_update_submitted_qc>May 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic melanoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Stage IV melanoma</keyword>
  <keyword>Cutaneous</keyword>
  <keyword>Mucosal</keyword>
  <keyword>Ocular</keyword>
  <keyword>Dabrafenib</keyword>
  <keyword>Trametinib</keyword>
  <keyword>DRB436</keyword>
  <keyword>TMT212</keyword>
  <keyword>Compassionate Use</keyword>
  <keyword>Cohort</keyword>
  <keyword>Expanded access</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04489433
org study id: CDRB436B2005CM
nct id: NCT04489433
lead sponsor: 
The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in
      combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed
      with metastatic melanoma BRAF mutation-positive.
The patient's Treating Physician should follow the suggested treatment guidelines and comply
      with all local health authority regulations.

      The requesting Treating Physician submitted a request for access to drug (often referred to
      as Compassionate Use) to Novartis which was reviewed and approved by the medical team
      experienced with the drug and indication.

      This program will provide access to patients until:

        -  All participating countries have received marketing authorization and product is
           commercially available and accessible to all participating patient(s) or

        -  Alternative treatment options are available and/or

        -  In case of changes in the safety profile or a lack of overall efficacy of the product.
expanded access type treatment: Yes
intervention type: Drug
intervention name: Dabrafenib and Trametinib
description: The starting dose of the combination treatment will be administered as follows:
Dabrafenib, 150 mg, twice daily (BID);
Trametinib, 2.0 mg, once daily (QD)
intervention type: Drug
intervention name: Dabrafenib
description: If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.
intervention type: Drug
intervention name: Trametinib
description: If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.
criteria: 
gender: All
minimum age: 18 Years
maximum age: 100 Years
healthy volunteers: No
last name: Novartis Pharmaceuticals
phone: +41613241111
email: novartis.email@novartis.com
last name: Novartis Pharmaceuticals
phone: +81337978748
responsible party type: Sponsor
mesh term: Melanoma
mesh term: Trametinib
mesh term: Dabrafenib